172 related articles for article (PubMed ID: 33644483)
21. Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson's disease: preliminary cost-consequence analysis of the PD COMM pilot randomised controlled trial.
Scobie S; Jowett S; Lambe T; Patel S; Woolley R; Ives N; Rick C; Smith C; Brady MC; Clarke C; Sackley C
Pilot Feasibility Stud; 2021 Aug; 7(1):154. PubMed ID: 34372913
[TBL] [Abstract][Full Text] [Related]
22. The impact of Lee Silverman Voice Treatment (LSVT LOUD®) on voice, communication, and participation: Findings from a prospective, longitudinal study.
Bryans LA; Palmer AD; Anderson S; Schindler J; Graville DJ
J Commun Disord; 2021; 89():106031. PubMed ID: 33259945
[TBL] [Abstract][Full Text] [Related]
23. Effects of an extended version of the lee silverman voice treatment on voice and speech in Parkinson's disease.
Spielman J; Ramig LO; Mahler L; Halpern A; Gavin WJ
Am J Speech Lang Pathol; 2007 May; 16(2):95-107. PubMed ID: 17456888
[TBL] [Abstract][Full Text] [Related]
24. Treating disordered speech and voice in Parkinson's disease online: a randomized controlled non-inferiority trial.
Constantinescu G; Theodoros D; Russell T; Ward E; Wilson S; Wootton R
Int J Lang Commun Disord; 2011; 46(1):1-16. PubMed ID: 21281410
[TBL] [Abstract][Full Text] [Related]
25. Intensive voice treatment (LSVT) for patients with Parkinson's disease: a 2 year follow up.
Ramig LO; Sapir S; Countryman S; Pawlas AA; O'Brien C; Hoehn M; Thompson LL
J Neurol Neurosurg Psychiatry; 2001 Oct; 71(4):493-8. PubMed ID: 11561033
[TBL] [Abstract][Full Text] [Related]
26. Comparison of speech and language therapy techniques for speech problems in Parkinson's disease.
Herd CP; Tomlinson CL; Deane KH; Brady MC; Smith CH; Sackley CM; Clarke CE
Cochrane Database Syst Rev; 2012 Aug; 2012(8):CD002814. PubMed ID: 22895931
[TBL] [Abstract][Full Text] [Related]
27. Effects of the Lee Silverman Voice Treatment (LSVT® LOUD) on hypomimia in Parkinson's disease.
Dumer AI; Oster H; McCabe D; Rabin LA; Spielman JL; Ramig LO; Borod JC
J Int Neuropsychol Soc; 2014 Mar; 20(3):302-12. PubMed ID: 24524211
[TBL] [Abstract][Full Text] [Related]
28. Intensive Voice Treatment (Lee Silverman Voice Treatment [LSVT LOUD]) for Children With Down Syndrome: Phase I Outcomes.
Boliek CA; Halpern A; Hernandez K; Fox CM; Ramig L
J Speech Lang Hear Res; 2022 Apr; 65(4):1228-1262. PubMed ID: 35230877
[TBL] [Abstract][Full Text] [Related]
29. Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson's disease: a pilot randomised controlled trial (PD COMM pilot).
Sackley CM; Smith CH; Rick CE; Brady MC; Ives N; Patel S; Woolley R; Dowling F; Patel R; Roberts H; Jowett S; Wheatley K; Kelly D; Sands G; Clarke CE;
Pilot Feasibility Stud; 2018; 4():30. PubMed ID: 29344405
[TBL] [Abstract][Full Text] [Related]
30. Effects of an intensive voice treatment on articulatory function and speech intelligibility in children with motor speech disorders: A phase one study.
Langlois C; Tucker BV; Sawatzky AN; Reed A; Boliek CA
J Commun Disord; 2020; 86():106003. PubMed ID: 32505858
[TBL] [Abstract][Full Text] [Related]
31. Lee Silverman voice treatment (LSVT) mitigates voice difficulties in mild Parkinson's disease.
Saffarian A; Amiri Shavaki Y; Shahidi GA; Hadavi S; Jafari Z
Med J Islam Repub Iran; 2019; 33():5. PubMed ID: 31086784
[No Abstract] [Full Text] [Related]
32. Multidimensional voice assessment after Lee Silverman Voice Therapy (LSVT
Marchese MR; Proietti I; Longobardi Y; Mari G; Ausili Cefaro C; D'Alatri L
Acta Otorhinolaryngol Ital; 2022 Aug; 42(4):348-354. PubMed ID: 36254651
[TBL] [Abstract][Full Text] [Related]
33. Intensive voice treatment (LSVT®LOUD) for Parkinson's disease following deep brain stimulation of the subthalamic nucleus.
Spielman J; Mahler L; Halpern A; Gilley P; Klepitskaya O; Ramig L
J Commun Disord; 2011; 44(6):688-700. PubMed ID: 21724193
[TBL] [Abstract][Full Text] [Related]
34. Respiratory Responses to Two Voice Interventions for Parkinson's Disease.
Richardson K; Huber JE; Kiefer B; Kane C; Snyder S
J Speech Lang Hear Res; 2022 Oct; 65(10):3730-3748. PubMed ID: 36167066
[TBL] [Abstract][Full Text] [Related]
35. Long-term effects of Lee Silverman Voice Treatment on daily voice use in Parkinson's disease as measured with a portable voice accumulator.
Körner Gustafsson J; Södersten M; Ternström S; Schalling E
Logoped Phoniatr Vocol; 2019 Oct; 44(3):124-133. PubMed ID: 29447488
[TBL] [Abstract][Full Text] [Related]
36. Neurobehavioral Effects of LSVT
Li Y; Tan M; Fan H; Wang EQ; Chen L; Li J; Chen X; Liu H
Front Neurosci; 2021; 15():624801. PubMed ID: 33716652
[TBL] [Abstract][Full Text] [Related]
37. Neural Correlates of Hypokinetic Dysarthria and Mechanisms of Effective Voice Treatment in Parkinson Disease.
Baumann A; Nebel A; Granert O; Giehl K; Wolff S; Schmidt W; Baasch C; Schmidt G; Witt K; Deuschl G; Hartwigsen G; Zeuner KE; van Eimeren T
Neurorehabil Neural Repair; 2018 Dec; 32(12):1055-1066. PubMed ID: 30444176
[TBL] [Abstract][Full Text] [Related]
38. The impact of PD Check-In on self-management skills for maintenance of speech after intensive treatment.
Finnimore A; Theodoros D; Rumbach AF
Int J Lang Commun Disord; 2024 Feb; ():. PubMed ID: 38377119
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of Lee Silverman Voice Treatment (LSVT) on hypernasality in non-progressive dysarthria: the need for further research.
Wenke RJ; Theodoros D; Cornwell P
Int J Lang Commun Disord; 2010; 45(1):31-46. PubMed ID: 19565392
[TBL] [Abstract][Full Text] [Related]
40. Speech and swallowing disorders in Parkinson disease.
Sapir S; Ramig L; Fox C
Curr Opin Otolaryngol Head Neck Surg; 2008 Jun; 16(3):205-10. PubMed ID: 18475072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
